{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:25:27Z","timestamp":1792027527512,"version":"4.4.0"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Bloodstream infections due to antimicrobial-resistant\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            occur with increasing frequency and represent an important cause of morbidity and mortality. To date, the evaluation of pharmacokinetic-pharmacodynamic relationships for efficacy among patients with bacteremia has been limited. The objectives of these analyses were to evaluate relationships between microbiological and clinical responses for patients with\n            <jats:italic>S. aureus<\/jats:italic>\n            bacteremia and exposures for oritavancin, a novel bactericidal glycopeptide in development. Bayesian oritavancin exposure predictions, following treatment with 5, 6.5, 8, or 10 mg\/kg of body weight\/day, were derived using a validated population pharmacokinetic model for 55 patients with\n            <jats:italic>S. aureus<\/jats:italic>\n            bacteremia. Using classification and regression tree analysis, a breakpoint of the percentage of the dosing interval duration for which free-drug concentrations were above the MIC (free-drug % time &gt; MIC) of 22% was identified for microbiological response; the probabilities of success greater than or equal to and less than this value were 93% and 76%, respectively. Using logistic regression, a relationship was found between microbiological response and free-drug % time &gt; MIC (odds ratio = 4.42,\n            <jats:italic>P<\/jats:italic>\n            = 0.09, and odds ratio = 8.84,\n            <jats:italic>P<\/jats:italic>\n            = 0.05, when one patient, a medical outlier, was excluded). A similar relationship was found for clinical response. These results will be valuable in supporting dose selection of oritavancin for patients with\n            <jats:italic>S. aureus<\/jats:italic>\n            bacteremia.\n          <\/jats:p>","DOI":"10.1128\/aac.50.3.994-1000.2006","type":"journal-article","created":{"date-parts":[[2006,2,22]],"date-time":"2006-02-22T07:32:35Z","timestamp":1140593555000},"page":"994-1000","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":56,"title":["Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with\n            <i>Staphylococcus aureus<\/i>\n            Bacteremia"],"prefix":"10.1128","volume":"50","author":[{"given":"Sujata M.","family":"Bhavnani","sequence":"first","affiliation":[{"name":"Cognigen Corporation, Buffalo, New York"},{"name":"School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Passarell","sequence":"additional","affiliation":[{"name":"Cognigen Corporation, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel S.","family":"Owen","sequence":"additional","affiliation":[{"name":"Cognigen Corporation, Buffalo, New York"},{"name":"Harrison School of Pharmacy, Auburn University, Auburn, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Loutit","sequence":"additional","affiliation":[{"name":"InterMune, Inc., Brisbane, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven B.","family":"Porter","sequence":"additional","affiliation":[{"name":"InterMune, Inc., Brisbane, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Cognigen Corporation, Buffalo, New York"},{"name":"School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2793-2797.2001"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90349-3"},{"key":"e_1_3_2_4_2","first-page":"720","volume":"92","year":"1982","unstructured":"Bjornson, H. S., R. Colley, R. H. Bower, V. P. Duty, J. T. Schwartz-Fulton, and J. E. Fischer. 1982. Association between microorganism growth at the catheter insertion site and colonization of the catheter in patients receiving total parenteral nutrition. Surgery92:720-727.","journal-title":"Surgery"},{"key":"e_1_3_2_5_2","unstructured":"Bonapace C. R. In vitro\/animal models to support dosage selection: FDA perspective. IDSA\/ISAP\/FDA workshop April 16 2004. [Online.] http:\/\/www .fda.gov\/cder\/drug\/antimicrobial\/FDAIDSAISAPPresentations\/Chuck%20 Bonapace.ppt\n."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1700-1706.2003"},{"key":"e_1_3_2_7_2","first-page":"1417","volume":"50","year":"1990","unstructured":"Cercenado, E., J. Ena, M. Rodriguez-Creixems, I. Romero, and E. Bouza. 1990. A conservative procedure for the diagnosis of catheter-related infections. Arch. Intern. Med.50:1417-1420.","journal-title":"Arch. Intern. Med."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1073"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.3.672"},{"key":"e_1_3_2_10_2","unstructured":"Lesko L. Proposal for end-of-phase 2A (EOP2A) meetings FDA Advisory Committee for Pharmaceutical Science Clinical Pharmacology Subcommittee November 17 2003. [Online.] http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/slides\/3998s1.htm\n."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.69-74.2002"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.6.811"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.1.79"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.3.627"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/37.4.703"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197706092962301"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530270029027"},{"key":"e_1_3_2_18_2","first-page":"1598","volume":"275","year":"1994","unstructured":"Pittet, D., D. Tarara, and R. P. Wenzel. 1994. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA275:1598-1601.","journal-title":"JAMA"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.2.125"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.50.3.994-1000.2006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.50.3.994-1000.2006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:59:16Z","timestamp":1645469956000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.50.3.994-1000.2006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1128\/AAC.50.3.994-1000.2006"],"URL":"https:\/\/doi.org\/10.1128\/aac.50.3.994-1000.2006","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"2005-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-12-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}